Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?

被引：14

作者：

Chin, Paul K. L. ^{[1
]}

Vella-Brincat, Jane W. A. ^{[1
]}

Barclay, Murray L. ^{[1
]}

Begg, Evan J. ^{[1
]}

机构：

[1] Christchurch Hosp, Dept Clin Pharmacol, Christchurch 8011, New Zealand

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 74卷 / 05期

关键词：

THROMBIN INHIBITOR DABIGATRAN; VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; PHARMACODYNAMICS; PHARMACOKINETICS; PREVENTION; ENOXAPARIN; REPLACEMENT; WARFARIN;

D O I：

10.1111/j.1365-2125.2012.04266.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：734 / 740

页数：7

共 21 条

[1]

Anon, 2011, PRADAXA 75 MG HARD C

[2] Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran [J].

Beasley, B. Nhi ;

Unger, Ellis F. ;

Temple, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1788-1790

[3] A unified pharmacokinetic approach to individualized drug dosing [J].

Begg, Evan J. ;

Chin, Paul K. L. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (03) :335-339

[4] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].

Blech, Stefan ;

Ebner, Thomas ;

Ludwig-Schwellinger, Eva ;

Stangier, Joachim ;

Roth, Willy .

DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399

[5] Emergency Hospitalizations for Adverse Drug Events in Older Americans [J].

Budnitz, Daniel S. ;

Lovegrove, Maribeth C. ;

Shehab, Nadine ;

Richards, Chesley L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (21) :2002-2012

[6] A systematic review of the associations between dose regimens and medication compliance [J].

Claxton, AJ ;

Cramer, J ;

Pierce, C .

CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310

[7] Newly Identified Events in the RE-LY Trial [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Reilly, Paul A. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) :1875-1876

[8] Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial [J].

Eikelboom, John W. ;

Wallentin, Lars ;

Connolly, Stuart J. ;

Ezekowitz, Mike ;

Healey, Jeff S. ;

Oldgren, Jonas ;

Yang, Sean ;

Alings, Marco ;

Kaatz, Scott ;

Hohnloser, Stefan H. ;

Diener, Hans-Christoph ;

Franzosi, Maria Grazia ;

Huber, Kurt ;

Reilly, Paul ;

Varrone, Jeanne ;

Yusuf, Salim .

CIRCULATION, 2011, 123 (21) :2363-U72

[9] Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial [J].

Eriksson, B. I. ;

Dahl, O. E. ;

Rosencher, N. ;

Kurth, A. A. ;

Van Dijk, N. ;

Frostick, S. P. ;

Kalebo, P. ;

Christiansen, A. V. ;

Hantel, S. ;

Hettiarachchi, R. ;

Schnee, J. ;

Buller, H. R. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) :2178-2185

[10] Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].

Eriksson, Bengt I. ;

Dahl, Ola E. ;

Rosencher, Nadia ;

Kurth, Andreas A. ;

van Dijk, C. Niek ;

Frostick, Simon P. ;

Prins, Martin H. ;

Hettiarachchi, Rohan ;

Hantel, Stefan ;

Schnee, Janet ;

Bueller, Harry R. .

LANCET, 2007, 370 (9591) :949-956

← 1 2 3 →